Development of a Population-Based Cost-Effectiveness Model of Chronic Graft-Versus-Host Disease in Spain

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages 1774-1787

  Crespo, Carlos ^a,b   Pérez Simón, José Anton ^c   Rodríguez, José Manuel ^d   Sierra, Jordi ^e   Brosa, Max ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Oblikue Consulting   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d JOHNSON AND JOHNSON   (United States)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Chronic graft; Cost effectiveness; Extracorporeal photopheresis; Host disease

Indexed keywords

ENOXAPARIN; IMATINIB; METHOXSALEN; RITUXIMAB;

ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COST EFFECTIVENESS ANALYSIS; EXTRACORPOREAL PHOTOPHERESIS; HEALTH CARE UTILIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PUVA; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SPAIN; TREATMENT OUTCOME; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHRONIC DISEASE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; GRAFT VS HOST DISEASE; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; NEEDS ASSESSMENT; PHOTOPHERESIS; PIPERAZINES; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864595821     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.029     Document Type: Article

References (65)

1. ONT 2010, The Spanish National Transplant Organization (ONT) tumor registry. [Report 2010: hematopoietic stem cell transplant], Accessed June 14, 2011. http://www.ont.es/infesp/Memorias/Memoria_tph_2010p1.pdf.
2. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft versus host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
3. Pidala J., Anasetti C., Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009, 114:7-19.
4. Pasquini M.C. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008, 21:193-204.
5. Barton-Burke M., Dwinell D.M., Kafkas L., et al. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Oncology (Williston Park) 2008, 22(11 Suppl Nurse Ed):31-45.
6. Pérez-Simón J.A., Encinas C., Silva F., et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes of Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 2008, 14:1163-1171.
7. Filipovich A.H. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:251-257.
8. Wolff D., Schleuning M., von Harsdorf S., et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1-17.
9. Bolaños-Meade J., Vogelsang G.B. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005, 12:40-44.
10. Pérez-Simón J.A., Sánchez-Abarca I., Díez-Campelo M., et al. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006, 66:1041-1057.
11. Knobler R.M., Trautinger F., Graninger W., et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol 1993, 28:580-584.
12. Edelson R., Berger C., Gasparro F., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987, 316:297-303.
13. Baird K., Wayne A.S. Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease. Transfus Apher Sci 2009, 41:209-216.
14. Developing NICE clinical guidelines: The guidelines manual 2009 National Institute for Health and Clinical Excellence (NICE), Accessed September 20, 2010. http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp.
15. López-Bastida J., Oliva J., Antoñanzas F., et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010, 11:513-520.
16. Consumer Price Index INE (National Statistics Institute), Accessed April 15, 2012. http://www.ine.es.
17. Weinstein M.C. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006, 24:1043-1053.
18. Burton P., Bryon S., Robinson S. Modelling in the economic evaluation of healthcare: selecting the appropriate approach. J Health Serv Res Policy 2004, 9:110-118.
19. Furiak N.M., Ascher-Svanum H., Klein R.W., et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011, 27:713-730.
20. Lee S.J., Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 134-141.
21. Scarisbrick J.J., Taylor P., Holtick U., et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008, 158:659-678.
22. Bolwell B., Fishleder A., Lichtin A., et al. Photopheresis in the treatment of chronic graft versus-host disease (cGvHD). Blood 1990, 76:529a.
23. Bloom E.J., Telang G.H., Jegosothy B.V. Extracorporeal photochemotherapy in the treatment of chronic graft-versus-host disease after allogenic bone marrow transplantation. American Society of Clinical Oncology Annual Meeting 1991, 19-21.
24. Owsianowski M., Gollnick H., Siegert W., et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994, 14:845-848.
25. Sniecinski I., Smith B., Parker P.M., Dagis A. Extracorporeal photochemotherapy for treatment of drug resistant chronic graft-versus-host disease. J Clin Aphresis 1995, 10:51. Abstract.
26. Balda B.R., Kostantinow A., Starz H., et al. Extracorporeal photochemotherapy as an effective treatment modality in chronic graft-versus-host disease. J Eur Acad Dermatol Venereol 1996, 7:155-162.
27. Crovetti G., Carabelli A., Bertani E. Case report: chronic graft versus-host disease (cGvHD) treated with extracorporeal photochemotherapy (ECP). Florence, Italy: Sixth World Apheresis Association Meeting 1996, 137a.
28. Abhvankar S., Godder K., Chiang K.Y., et al. Extracorporeal photopheresis (ECP) with UVADEX for the treatment of chronic graft-versus-host disease (cGvHD). J Exp Hematol 1998, 26:8.
29. Miller J.L., Goodman S.A., Stricklin G.P., Lloyd E.K. Extracorporeal photochemotherapy in the treatment of graft-versus-host disease. Abstract Book IBMTR/ABMTR Meeting Keystone Resort Colorado 1998, 7a.
30. Sniecinski I., Parker P., Dagis A., Smith B. Extracorporeal photopheresis (EP) is effective treatment for chronic refractory graft versus host disease. J Am Soc Hematol 1998, 92:454.
31. Zic J.A., Miller J.L., Stricklin G.P., King L.E. The North American experience with photopheresis. Ther Apher 1999, 3:50-62.
32. Biagi E., Perseghin P., Buscemi F., et al. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft-versus-host disease. Haematologica 2000, 85:329-330.
33. Alcindor T., Gorgun G., Miller K.B., et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001, 98:1622-1625.
34. Gorgun G., Miller K.B., Foss F.M. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100:941-947.
35. Perseghin P., Dassi M., Balduzzi A., et al. Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). J Clin Apher 2002, 17:65-71.
36. Biagi E., Di Biaso I., Leoni V., et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007, 84:31-39.
37. Flowers M.E., Apperley J.F., van Besien K., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008, 112:2667-2674.
38. Jagasia M.H., Savani B.N., Stricklin G., et al. Classic and overlap chronic graft-versus-host disease (cGvHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009, 15:1288-1295.
39. Pérez-Carmona L., Harto-Castaño A., Díez-Recio E., Jaén-Olasolo P. Extracorporeal photopheresis in dermatology [article in Spanish]. Actas Dermosifiliogr 2009, 100:459-471.
40. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft versus host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
41. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody-treatment in 6 patients with therapy-refractory chronic graft versus host disease. Blood 2004, 104:2603-2606.
42. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft versus host disease. Leukemia 2006, 20:172-173.
43. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
44. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
45. von Bonin M., Oelschlagel U., Radke J., et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008, 86:875-879.
46. Mohty M., Marchetti N., El-Cheikh J., et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008, 41:909-911.
47. Teshima T., Nagafuji K., Henzan H., et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009, 90:253-260.
48. Peterson J.D., Chan L.S. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag 2009, 5:1-7.
49. Magro L., Catteau B., Coiteux V., et al. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008, 42:757-760.
50. Stadler M., Ahlborn R., Kamal H., et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009, 114:3718-3719.
51. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114:719-722.
52. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
53. Heim D., Ebnöther M., Meyer-Monard S., et al. G-CSF for imatinib-induced neutropenia. Leukemia 2003, 17:805-807.
54. Grant C., Wilson W.H., Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2010, 18:49-54.
55. Spanish cost database. Oblikue Consulting 2010, e-Salud, Accessed September 20, 2010. http://www.oblikue.com.
56. Stafford M., Gavriel S., et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. Health Qual Life Outcomes 2008, 6:84.
57. General Spanish Council of Pharmacists2010, Accessed September 20, 2010. http://www.portalfarma.com.
58. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006, 107:3074-3080.
59. Claxton K., Schupher M., McCabe C., et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005, 14:339-347.
60. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000, 17:479-500.
61. Fenwick E., Marshall D.A., Levy A.R., Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006, 6:52.
62. Rodríguez J.M., Pérez F., Crespo C., et al. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ 2011 Jun 10, [Epub ahead of print]. http://dx.doi.org/10.1007/s10198-011-0326-y.
63. de la Cámara R., Jarque I., Sanz M.A., et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 2010, 45:925-932.
64. Dall'Amico R., Livi U., Milano A., et al. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995, 60:45-49.
65. Dall'Amico R., Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002, 6:296-304.